الفهرس 
Hepatitis C Virus
HCV proteins and drug targets:Only 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
Egypt has the highest known prevalence rate of HCV globally till
2016 so EMOH launched huge nationwide campaigns to treat patients with chronic HCV with the latest and most effective therapies, promoting Sovaldi as its’ primary treatment. In July 2015, the FDA approved the clinical use of daclatasvir plus sofosbuvir with or without ribavirin for 12 weeks against HCV genotype
1 or 3 infections. The current study was designed to detect the effect of (Sofosbuvir/ Daclatasvir) combination therapy on audio-vestibular systems in 20 patients with chronic Hepatitis C and all audiological and vestibular tests
were done before starting the treatment and after completion of treatment